The future of immunotherapy in the treatment of small cell lung cancer

Oncologist

Volumn 21, Issue 8, 2016, Pages 910-921

  Horn, Leora ^a   Reck, Martin ^b   Spigel, David R ^c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocyte antigen 4; Immune checkpoint pathways; Immunotherapy; Programmed cell death protein 1; Small cell lung cancer

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 2; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; EATON LAMBERT SYNDROME; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; METASTASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMALL CELL LUNG CANCER; T LYMPHOCYTE ACTIVATION; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; NEOPLASM RECURRENCE, LOCAL; PROGRAMMED CELL DEATH 1 RECEPTOR; SMALL CELL LUNG CARCINOMA;

EID: 84981554895     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0523     Document Type: Article

References (73)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-1380
2. Rudin CM, Ismaila N, Hann CL et al.Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol 2015;33: 4106-4111
3. Früh M, De Ruysscher D, Popat S et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(suppl 6):vi99-vi105
4. George J, Lim JS, Jang SJ et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524:47-53
5. Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 2012;25(suppl 1):S18-S30
6. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines. 2nd ed. Chest 2007;132:324S-339S
7. Chan BA, Coward JI. Chemotherapy advances in small-cell lung cancer. J Thorac Dis 2013;5(suppl 5): S565-S578
8. Sundstrøm S, Bremnes RM, Kaasa S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years’ follow-up. J Clin Oncol 2002;20:4665-4672
9. Hanna N, Bunn PA Jr., LangerCet al.Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043
10. Lara PN Jr., Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27: 2530-2535
11. Zhi XY, Yu JM, Shi YK. Chinese guidelines on the diagnosis and treatment of primary lung cancer (2015 version). Cancer 2015;121(suppl 17): 3165-3181
12. Shi Y, Xing P, Fan Y et al. Current small cell lung cancer treatment in China. Thorac Cancer 2015;6: 233-238
13. Hurwitz JL, McCoy F, Scullin P et al. New advances in the second-line treatment of small cell lung cancer. The Oncologist 2009;14:986-994
14. von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent smallcell lung cancer. J Clin Oncol 1999;17:658-667
15. Onoda S, Masuda N, Seto T et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-5453
16. Asai N, Ohkuni Y, Kaneko N et al. Relapsed small cell lung cancer: Treatment options and latest developments. Ther Adv Med Oncol 2014;6:69-82
17. Lally BE, Urbanic JJ, Blackstock AW et al. Small cell lung cancer: Have we made any progress over the last 25 years? The Oncologist 2007;12: 1096-1104
18. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565-1570
19. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480: 480-489
20. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264
21. Vesely MD, Kershaw MH, Schreiber RD et al. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-271
22. Steer HJ, Lake RA, Nowak AK et al. Harnessing the immune response to treat cancer. Oncogene 2010;29:6301-6313
23. Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer,immunity, and the brain. Proc Natl Acad Sci USA 1996;93:4529-4536
24. Maddison P, Newsom-Davis J, Mills KR et al. Favourable prognosis in Lambert-Eatonmyasthenic syndrome and small-cell lung carcinoma. Lancet 1999;353:117-118
25. Wang W, Hodkinson P, McLaren F et al. Histologic assessment of tumor-associated CD45 (1) cell numbers is an independent predictor of prognosis in small cell lung cancer. Chest 2013;143: 146-151
26. Koyama K, Kagamu H, Miura S et al. Reciprocal CD41 T-cell balance of effector CD62Llow CD41 and CD62LhighCD251 CD41 regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008;14:6770-6779
27. Tani T, Tanaka K, Idezuka J et al. Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol 2008;196:166-169
28. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128
29. Rudin CM, Durinck S, Stawiski EW et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-1116
30. Peifer M, Fernández-Cuesta L, Sos ML et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. NatGenet 2012;44:1104-1110
31. Wolchok JD, Saenger Y. Themechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The Oncologist 2008;13(suppl 4):2-9
32. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-723
33. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526
34. Reck M, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, doubleblind, multicenter phase 2 trial. Ann Oncol 2013;24: 75-83
35. Masters G, Barreto L, Girit E et al. Antitumor activity of cytotoxic T-lymphocyte antigen-4 blockade alone or combined with paclitaxel, etoposide orgemcitabine in murinemodels. J Immunother 2009; 32:994a
36. Lee F, Jure-Kunkel MN, Salvati ME. Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther Adv Med Oncol 2011;3:11-25
37. Thomas P, Castelnau O, PaillotinDet al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: A Groupe Français de Pneumo-Canc ´erologie study. J Clin Oncol 2001; 19:1320-1325
38. Reck M, von Pawel J, Macha HN et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 2003;95:1118-1127
39. Bristol-Myers Squibb. Bristol-Myers Squibb reports second quarter financial results. July 23, 2015. Available at http://news.bms.com/pressrelease/financial-news/bristol-myers-squibb-reportssecond-quarter-financial-results. Accessed May 19, 2016
40. Ottensmeier IG, Cross N, Maishman T et al. 1477P-A novel phase II trial of ipilimumab, carboplatin and etoposide (ICE) for the first line treatment of extensive stage small cell lung cancer (SCLC). Ann Oncol 2014;25(suppl 4):iv511-iv516
41. OPDIVO (Nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; May 2016
42. European Medicines Agency. Opdivo. Available at http://www.ema.europa.eu/ema/index.jsp?curl5pages/medicines/human/medicines/003985/human_ med_001876.jsp&mid5WC0b01ac058001d124. AccessedMay 19, 2016
43. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmall-cell lung cancer. N Engl J Med 2015;373: 1627-1639
44. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373: 123-135
45. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015;16:257-265
46. Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ; Merck Sharp & Dohme Corp; December 2015
47. European Medicines Agency. Keytruda. Available at http://www.ema.europa.eu/ema/index.jsp?curl5pages/medicines/human/medicines/003820/human_ med_001886.jsp&mid5WC0b01ac058001d124.
48. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non AccessedMay 19, 2016-small-cell lung cancer. N Engl J Med 2015;372:2018-2028
49. Calvo E, Lóopez-Martin JA, Bendell J et al. Nivolumab monotherapy or in combination with ipilimumab for treatment of recurrent small cell lung cancer (SCLC). Presented at: 18th ECCO-40th ESMO European Cancer Congress Annual Meeting; September 25-29, 2015; Vienna, Austria.
50. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl JMed 2013;369:122-133
51. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.NEngl JMed 2015; 373:23-34
52. von Pawel J, Jotte R, Spigel DR et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014;32:4012-4019
53. Rizvi NA, Gettinger SN, Goldman JW et al. Safety and efficacy of first-line nivolumab and ipilimumab in non-small cell lung cancer. 16thWorld Conference on Lung Cancer. Abstract ORAL02.05. Presented September 7, 2015
54. Ott PA, Elez E, Hiret S et al. Pembrolizumab for extensive stage SCLC: Efficacy and relationship with PD-L1 expression. Presented at: 16th World Conference on Lung Cancer; September 6-9, 2015; Denver, CO. Presentation 3285
55. Park JJ, Omiya R, Matsumura Y et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010;116:1291-1298
56. Rizvi NA, Brahmer JR, Ou S-HI et al. Safety and clinical activity ofMEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Presented at: American Society of Clinical Oncology 2015 AnnualMeeting; May 29-June 2, 2015; Chicago, IL, USA. Poster #354
57. Liu SV, Powderly JD, Camidge DR et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Presented at: American Society of Clinical Oncology 2015 Annual Meeting; May 29-June 2, 2015; Chicago, IL, USA. Poster #352
58. Pillai RN, Aisner J, Dahlberg SE et al. Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): An Eastern Cooperative Oncology Group study (E6501). Cancer Chemother Pharmacol 2014; 74:177-183
59. Zarogoulidis K, Ziogas E, Boutsikou E et al. Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: A phase II, randomized study. Drug Des Devel Ther 2013;7:611-617
60. Krug LM, Ragupathi G, Hood C et al. Immunization with N-propionyl polysialic acid-KLH conjugatein patients with small cell lung cancer is safeand induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci. Cancer Immunol Immunother 2012;61:9-18
61. Krug LM, Ragupathi G, Hood C et al. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin Cancer Res 2004;10: 6094-6100
62. Antonia SJ, Mirza N, Fricke I et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-887
63. Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005;23: 6854-6864
64. Whiteside TL. Immune responses to cancer: Are they potential biomarkers of prognosis? Front Oncol 2013;3:107
65. Yuan J, Hegde PS, Clynes R et al. Novel technologies and emerging biomarkers for personalizedcancerimmunotherapy. JImmunother Cancer 2016;4:3
66. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8:823-859
67. Taube JM, Klein A, Brahmer JR et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20: 5064-5074
68. Kerr KM, Tsao MS, Nicholson AG et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art? J Thorac Oncol 2015;10:985-989
69. Patel SP, Kurzrock R. PD-L1 Expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847-856
70. Phillips T, Simmons P, Inzunza HD et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 2015; 23:541-549
71. Ishii H, Azuma K, Kawahara A et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 2015;10:426-430
72. Schultheis AM, Scheel AH, Ozretić L et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 2015;51:421-426
73. Pietanza C, Sigel DR, Baure T et al. Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). Presented at: 18th Congress of the European CanCer Organisation (ECCO) and the 40th Congress of the European Society for Medical Oncology (ESMO); September 25-29, 2015; Vienna, Austria. Abstract LBA 7